<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02045602</url>
  </required_header>
  <id_info>
    <org_study_id>P-VCNA-001</org_study_id>
    <secondary_id>2012-005555-16</secondary_id>
    <nct_id>NCT02045602</nct_id>
  </id_info>
  <brief_title>Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multicenter, Open-label, Dose Escalation Study of Intravenous Administration of VCN-01 Oncolytic Adenovirus With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VCN Biosciences, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VCN Biosciences, S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of VCN-01 either&#xD;
      administered alone or in combination with Abraxane®/Gemcitabine, and to determine the&#xD;
      recommended phase II dose of VCN-01 alone or in combination with Abraxane®/Gemcitabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of three parts:&#xD;
&#xD;
        -  Part I is a dose escalation study to determine the safety and tolerability of a single&#xD;
           intravenous injection of VCN-01 alone&#xD;
&#xD;
        -  In Part II the safety and tolerability of the two highest VCN-01 tolerable doses from&#xD;
           part I will be evaluated in combination with Abraxane®/Gemcitabine.&#xD;
&#xD;
        -  In Part III the safety and tolerability of the two highest VCN-01 tolerable doses from&#xD;
           part I will be evaluated in combination with Abraxane®/Gemcitabine in a &quot;delayed&quot;&#xD;
           schedule compared with Part II.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability by means of Adverse Events (AEs) and laboratory data</measure>
    <time_frame>At least 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) by determination of highest feasible dose (MFD) and any Dose Limiting Toxicities</measure>
    <time_frame>At least 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of VCN-01 in tumor</measure>
    <time_frame>Day 8-10</time_frame>
    <description>Determination of VCN-01 by analyzing viral genome copies in tumor biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Pharmacokinetics</measure>
    <time_frame>Up to 48 h</time_frame>
    <description>Determination of VCN-01 half-life by analyzing viral genome copies in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Shedding</measure>
    <time_frame>Up to day 28</time_frame>
    <description>And at least up to 6 months follow-up in patients at the Maximum Tolerated Dose (MTD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibodies anti-VCN-01</measure>
    <time_frame>30 days after end of treatment phase</time_frame>
    <description>At least up to 6 months follow-up in patients at the MTD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity by Overall Response Rate (ORR)</measure>
    <time_frame>CT or MRI scans every 8 weeks until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity by Progression Free Survival (PFS)</measure>
    <time_frame>CT or MRI scans every 8 weeks until disease progression</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Locally Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Part I: Dose Escalation, Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous injection of VCN-01 oncolytic adenovirus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: Dose Escalation, Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part III: Dose Escalation, Combination, &quot;delayed&quot; schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>VCN-01</intervention_name>
    <description>Genetically modified human adenovirus encoding human PH20 hyaluronidase</description>
    <arm_group_label>Part I: Dose Escalation, Single Agent</arm_group_label>
    <arm_group_label>Part II: Dose Escalation, Combination</arm_group_label>
    <arm_group_label>Part III: Dose Escalation, Combination, &quot;delayed&quot; schedule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m2 intravenous administration</description>
    <arm_group_label>Part II: Dose Escalation, Combination</arm_group_label>
    <arm_group_label>Part III: Dose Escalation, Combination, &quot;delayed&quot; schedule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane®</intervention_name>
    <description>125 mg/m2 intravenous administration</description>
    <arm_group_label>Part II: Dose Escalation, Combination</arm_group_label>
    <arm_group_label>Part III: Dose Escalation, Combination, &quot;delayed&quot; schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/Female patients aged 18 years or over&#xD;
&#xD;
          -  Patients must provide written informed consent&#xD;
&#xD;
          -  Part I: Patients with histologically confirmed, locally advanced or metastatic solid&#xD;
             tumors. Part II and Part III: Patients with histologically confirmed, pancreatic&#xD;
             adenocarcinoma for which the established therapy is Abraxane®/Gemcitabine (clinical&#xD;
             standard of care)&#xD;
&#xD;
          -  Life expectancy above 3 months&#xD;
&#xD;
          -  Patients willing to comply with treatment follow-up&#xD;
&#xD;
          -  ECOG Performance status 0 or 1&#xD;
&#xD;
          -  Adequate baseline organ function (hematologic, liver, renal and nutritional)&#xD;
&#xD;
          -  Use a reliable method of contraception in fertile men and women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection or other serious illness or autoimmune disease&#xD;
&#xD;
          -  Treatment with live attenuated vaccines in the last three weeks&#xD;
&#xD;
          -  Known chronic liver disease (liver cirrhosis, chronic hepatitis)&#xD;
&#xD;
          -  Treatment with another investigational agent within its five half-lives prior to&#xD;
             VCN-01 infusion&#xD;
&#xD;
          -  Viral syndrome diagnosed during the two weeks before inclusion&#xD;
&#xD;
          -  Chronic immunosuppressive therapy&#xD;
&#xD;
          -  Concurrent malignant hematologic or solid disease&#xD;
&#xD;
          -  Pregnancy or lactation. Patients must agree to use effective contraception or be&#xD;
             surgically sterile.&#xD;
&#xD;
          -  Patients receiving full-dose anticoagulant / antiplatelet therapy&#xD;
&#xD;
          -  Adequate levels of neutralizing antibodies against adenovirus&#xD;
&#xD;
          -  Patients with Li Fraumeni syndrome or with previous known retinoblastoma protein&#xD;
             pathway germinal deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia</name>
      <address>
        <city>Hospitalet De Llobregat</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>25080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Oncolytic virus</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

